<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822132</url>
  </required_header>
  <id_info>
    <org_study_id>ALKIIT-KOR-034</org_study_id>
    <secondary_id>1R21DA033182-01A1</secondary_id>
    <nct_id>NCT01822132</nct_id>
  </id_info>
  <brief_title>Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade</brief_title>
  <official_title>Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to learn more about impulsive decision making in people who
      use methamphetamines. The investigators would like to know if a medication called naltrexone
      changes how people make decisions. The investigators would also like to know whether changes
      in decision making can be observed by MRI (magnetic resonance imaging).

      The research is conducted in Portland, OR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discounting Tasks</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neural Mapping</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methamphetamine use</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV risk behaviors</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral adherence</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Methamphetamine Abuse</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Extended release naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of intramuscular injection of 380mg extended-release naltrexone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One dose of intramuscular injection of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended release naltrexone</intervention_name>
    <arm_group_label>Extended release naltrexone</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Summary Inclusion Criteria:

          -  Diagnostic and Statistical Manual (DSM)-IV Methamphetamine Dependence

          -  Deemed healthy enough to participate by study physician

          -  Age 18-55

          -  Right handed

          -  English-speaking

        Summary Exclusion Criteria:

          -  Current opioid use in the last 30 days; opioid abuse or dependence within past 5 years

          -  Pregnancy

          -  MRI contraindications (e.g. metal in head).

        The research is conducted in Portland, OR.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T Korthuis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland VA Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>P. Todd Korthuis</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 20, 2017</submitted>
    <returned>October 17, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

